Cite

HARVARD Citation

    Weber, J. et al. (2015). Pre-treatment patient selection for nivolumab benefit based on serum mass spectra. Journal for immunotherapy of cancer. 3 (2), pp. 1-2. [Online]. 
  
Back to record